It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment.

If the pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives; however, molecular genetic testing cannot predict the occurrence of symptoms, or if they do occur, the age of onset, severity and type of symptoms, or rate of disease progression.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

In 20 pregnancies reported in 12 affected individuals, levodopa was continued without adverse effect in most. Two woman experienced remission resulting in a reduction or cessation of therapy. Two women reported mild deterioration of dystonia; an increase in dose was required in one. No fetal abnormalities were identified [Trender-Gerhard et al 2009].
